PARSIPPANY, N.J., April 20, 2023 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), one of the largest pure-play diabetes care companies in the world, will host a conference call to discuss its fiscal second quarter 2023 financial results, provide an operational update, and host a question and answer session, at 8:00 a.m. Eastern Time (ET) on Friday, May 12, 2023.
Those who would like to participate may access the live webcast here, or access the teleconference here. The live webcast can also be accessed via the company’s website at investors.embecta.com.
A webcast replay of the call will be available beginning at 11:00 a.m. ET on May 12, 2023, via the embecta investor relations website and archived on the website for one year.
About embecta
embecta is one of the largest pure-play diabetes care companies in the world, leveraging its nearly 100-year legacy in insulin delivery to empower people with diabetes to live their best life through innovative solutions, partnerships and the passion of approximately 2,000 employees around the globe. For more information, visit embecta.com or follow our social channels on LinkedIn, Facebook, Instagram and Twitter.
| Contacts: | |
| Media Christian Glazar Sr. Director, Corporate Communications 908-821-6922 This email address is being protected from spambots. You need JavaScript enabled to view it. | Investors Pravesh Khandelwal VP, Head of Investor Relations 551-264-6547 This email address is being protected from spambots. You need JavaScript enabled to view it. |
| Last Trade: | US$19.13 |
| Daily Change: | 0.39 2.08 |
| Daily Volume: | 187,038 |
| Market Cap: | US$1.110B |
September 03, 2024 August 09, 2024 | |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
